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Abstract
Identifying early predictors of infection outcome is important for the clinical management of HIV infection, and both viral
load and CD4+ T cell level have been found to be useful predictors of subsequent disease progression. Very high viral load
or extensively depleted CD4+ T cells in the acute phase often result in failure of immune control, and a fast progression to
AIDS. It is usually assumed that extensive loss of CD4+ T cells in the acute phase of HIV infection prevents the establishment
of robust T cell help required for virus control in the chronic phase. We tested this hypothesis using viral load and CD4+ T
cell number of SHIV-infected rhesus macaques. In acute infection, the lowest level of CD4+ T cells was a good predictor of
later survival; animals having less than 3.3% of baseline CD4+ T cells progressed to severe disease, while animals with more
than 3.3% of baseline CD4+ T cells experienced CD4+ T cell recovery. However, it is unclear if the disease progression was
caused by early depletion, or was simply a result of a higher susceptibility of an animal to infection. We derived a simple
relationship between the expected number of CD4+ T cells in the acute and chronic phases for a constant level of host
susceptibility or resistance. We found that in most cases, the depletion of CD4+ T cells in chronic infection was consistent
with the prediction from the acute CD4+ T cell loss. However, the animals with less than 3.3% of baseline CD4 T cells in the
acute phase were approximately 20% more depleted late in the infection than expected based on constant level of virus
control. This suggests that severe acute CD4 depletion indeed impairs the immune response.
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Introduction
The disease course in untreated human immunodeficiency virus
(HIV) infection consists of an early acute phase characterized by
extremely high viral loads and depletion of CD4+Tcells, followedby a
largely asymptomatic chronic phase with more moderate viral loads
and a slow loss of CD4+ T cell pool after partial recovery, and finally
emergence of immunodeficiency, opportunistic infections and death. A
similar but more rapid course of infection is seen in some non-human
primates models of HIV, using infections with simian and simian-
human immunodeficiency viruses (SIV and SHIV respectively).
Despite the differences in the disease course in the three types of
untreated infections, prolonged survival in HIV-1 [1], SIVmac [2]
and SHIV [3] was found to be linked to better viral control and
CD4+ T cell recovery during chronic phase. This is commonly
explained by the fact that CD4+ T cells play an important role in
immune control, providing help for both antibodies and CD8+ T
cells responses, which act to control infection. This is in agreement
with studies in mice where the absence of CD4+ T cells in primary
infection limits the subsequent ability of CD8+ T cells to respond
to secondary infection [1,4,5,6,7]. Thus, the development of AIDS
may occur when the density of CD4+ T cells drops below a limit
necessary to provide help (the threshold being around 200 cells/mL
of blood for HIV infection), leading to functional defects in CD8+
T cells and antibody-producing B cells.
Experiments using SHIV infection in rhesus macaques indicate
that the difference between immunodeficiency and prolonged
survival may be programmed early – the outcome could be traced
back to the degree of severity of viremia and CD4+ T cell loss
during the acute phase [1,2,3,8,9]. While a sustained better
immune response during the whole course of disease would
produce better viral control and CD4+ T cell preservation in all
phases of infection, an extremely severe acute phase could in
principle cause some additional irreversible damage to the
immune system, further compromising the long-term outcome.
Some indications for this effect come from SHIV challenge of
rhesus macaques. First, the degree of partial recovery of CD4+ T
cells after the acute phase seems to decrease as depletion in the
acute phase increases [3]. If the nadir in CD4+ T cells in acute
phase drops below approximately 20 cells/mL, there is no observed
partial recovery, and the animals experience a continued decline
in CD4+ T cell numbers and an increase in viral load [8]. In
addition, the disease outcome can be modulated by early
interventions that lower the acute viremia and preserve CD4+ T
cells at nadir, such as early passive administration of neutralizing
antibodies [10,11], early initiation of short-term antiretroviral
treatment [3] and vaccination [12,13]. This suggests that there
might exist a threshold in the severity of the acute disease, above
which later virus control is impaired. Very high peak viral loads or
a extremely low CD4+ T cell nadir [14] may lead to inflammation
and loss of lymph node architecture. Similarly, severe early or
prolonged loss of the CD4+ T cells in the gut mucosal barrier can
result in microbial translocation, which could cause generalized T
cell activation and tissue damage [15].
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e17180Although early and acute high viral load and severe CD4+ T
cell depletion are associated with a poor long-term outcome, it is
not clear that this is causative: if animals vary in their susceptibility
to infection, then highly susceptible animals would be expected to
have highly depleted CD4+ T cells and high viral loads in both the
acute and chronic phases of infection. Conversely, relatively
resistant animals would have a low viral load and well-preserved
CD4+ T cells in the acute and chronic phase. In this case, high
early viral load and severe CD4+ T cell depletion are associated
with a high late viral load and poor outcome, but the association is
not causative. Alternatively, a high early viral load and extensive
CD4 depletion may reduce CD4+ T cell help, and compromise
later immune control, which in this case would be causative.
In this paper, we explore the early predictors of long-term
outcome in SHIV89.6P infection. CXCR4-tropic SHIV89.6P
infection causes an accelerated disease progress with rapid
systemic loss of all CD4+ T cell phenotypes compared to
CCR5-tropic SIV and HIV. It has been used as a model for
studies of potential protective ability of vaccines against HIV-1
because it permits an early assessment of vaccine efficacy. Despite
their higher pathogenicity, X4-tropic SHIVs have proven to be
easier to control by vaccination than their more moderate CCR5-
tropic counterparts SIVmac and HIV [16,17]. This infection is
particularly suitable for our study because SHIV89.6P infects both
naı ¨ve and memory CD4+ T cells, and the loss of CD4+ T cells
measured in blood can be taken to approximately represent the
overall loss of CD4+ T cells in all anatomical compartments.
We first show that there is a threshold level of preservation of
CD4+ T cells and a threshold viral load in the acute phase that
correspond to the chronic phase thresholds of prolonged survival
(for longer than 600 days) in CXCR4-tropic SHIV89.6P infection
in rhesus macaques. We then use a modeling approach to show
that a simple theoretical relationship should exist between CD4 T
cell levels in acute and chronic infection under the conditions of
constant immune control during the whole course of disease.
However, if early CD4+ T cell depletion leads to impaired
immunity, then we would expect CD4 depletion in the chronic
phase of infection to be higher than predicted by this theoretical
relationship.
Our results show that there is indeed a well-defined threshold
level of remaining CD4 T cells in the acute phase that corresponds
to survival (and a corresponding somewhat less well-defined
limiting viral peak). Interestingly, animals that experience CD4
preservation above this threshold show the predicted relationship
between acute and chronic CD4+ T cell levels, suggesting immune
control is maintained. By contrast, animals with the fraction of
remaining CD4+ T cells in the acute phase lower than this
threshold also show significantly less than predicted remaining
CD4+ T cells in the chronic phase. This suggests that the
threshold level of CD4+ T cells predicting survival corresponds to
the minimum level of CD4+ T cells required to preserve immune
function in the chronic phase of infection.
Results
Predicting survival based on viral load and CD4+ T cell
number
In Figure 1 we show the longitudinal data for CD4+ T cell
count in peripheral blood compared to baseline (A) and plasma
viral load (B) for the 35 monkeys from the Shiver et al. study [13].
The baseline CD4 count was determined for each animal as the
average value of two pre-infection time points. We divided all
monkeys into two groups – those that survived for longer than 600
days (16 monkeys that we call ‘‘controllers’’), and those that died
or had to be euthanized earlier (19 monkeys that we call
‘‘progressors’’). Out of 21 vaccinated animals, 15 controlled the
infection and 6 were progressors (five DNA-based vaccines and
one MVA), while only one of 14 unvaccinated animals controlled
the infection. The timelines for the controllers are shown in red,
while the black lines represent the progressors. Progressors had
distinctly lower levels of CD4+ T cells at steady state and in the
acute phase than controllers, less CD4 recovery after the acute
phase than controllers, and higher viral set point and peak.
We first used diagnostic tests to determine how well our
classification of animals into controllers and progressors could be
reproduced on the basis of the fraction of remaining CD4 T cells
in the chronic phase and set point viral load instead of survival.
We were looking for the threshold values of the chronic CD4+ T
cell preserved fraction T
*/T0 and set point viral load that best
reproduced the division into progressors and controllers based on
survival longer than 600 days.
We considered progressors ‘‘positive’’ for early death and
controllers ‘‘negative’’. If we tested for early death using the
chronic depletion of CD4+ T cells, for each choice of the threshold
Figure 1. Measures of disease progress in SHIV-infected rhesus macaques. The animals are divided into controllers (red) that survived
longer than 600 days, and progressors (black) that were euthanized earlier due to severity of symptoms. (A) Longitudinal data for the CD4 T cells (in %
of baseline) and (B) viral load.
doi:10.1371/journal.pone.0017180.g001
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positive), ‘‘false positives’’ (controllers that test positive), true
negatives (controllers that test negative) and false negatives
(progressors that test negative). We chose the best threshold value
as the one that simultaneously maximized sensitivity, i.e. the
fraction of true positives out of all animals that test positive (Eq.1),
and the specificity, i.e. the fraction of true negatives out of all
animals that test negative (Eq.2). The summary of the measures of
accuracy of the two diagnostic tests is shown in Figure 2A-C
(sensitivity – full triangles; specificity – open inverted triangles) and
in Tables 1 and 2. The best classification was obtained with the
threshold chronic CD4 preservation of 24.1% and viral load of
4.83610
4 RNA copies/mL (dashed vertical lines in Figure 1A and
B) when values of sensitivity and specificity were the closest. The
Figure 2. Measures of accuracy of the survival tests based on CD4 preservation and viral load in the chronic and acute phases of
SHIV infection. (A–C) Chronic phase tests: (A) sensitivity and specificity of the test based on chronic level of CD4+ T cells; (B) sensitivity and
specificity of the test based on set point viral load, vertical dashed line represents the best choice of threshold; (C) ROC areas of the chronic phase
tests; (D–E) Acute phase tests: (D) sensitivity and specificity of the test based on acute level of CD4+ T cells; (E) sensitivity and specificity of the test
based on peak viral load, (F) ROC areas of the acute phase tests.
doi:10.1371/journal.pone.0017180.g002
Acute and Chronic Phase in SHIV
PLoS ONE | www.plosone.org 3 February 2011 | Volume 6 | Issue 2 | e17180overall accuracy of the tests based on chronic CD4 depletion or
viral load is compared in Figure 1C. A more accurate test would
be the one for which the area under the curve of sensitivity as a
function of (1-specificity), or the so-called ‘‘ROC area’’, is closer to
unity. Tests based on both chronic phase quantities had ROC
areas higher than 0.95, with CD4 preservation at 0.993 ranking a
little better than viral load at 0.977 (only one animal wrongly
classified at the best threshold of CD4 preservation, compared to
two for viral set point). The ROC areas for the two chronic phase
measures were not significantly different (p=0.459)
Next, we quantified how well we could separate controllers
from progressors on the basis of the acute phase measures. In
Figure 2D and E we plotted the sensitivity and specificity of the
tests based on CD4+ T cell levels in the acute phase (measured as
% of baseline) and on viral load, respectively. The best
combination of sensitivity and specificity was obtained for the
threshold level of CD4+ T cells in the acute phase at 3.3% of
baseline, and the threshold peak viral load of 4.79610
7 RNA
copies/mL (Tables 1 and 2). Specificity and sensitivity at the best
value of threshold were considerably higher for the test based on
CD4 preservation (,94%) than for the test based on viral load
(,86%), indicating that the test based on CD4 preservation is
more accurate. This is confirmed by the larger ROC area of the
acute CD4-based test (0.938, compared to 0.891 for the viral
peak). The ROC area of the test based on the CD4+ T cells
remaining in the acute phase was not significantly different from
the area of the test based on the CD4+ T cells in the chronic
phase (p=0.144). However, the ROC area of the test based on
peak viral load was significantly lower (p=0.0400) than the area
of the test based on the CD4+ T cells in the acute phase.
As expected, ROC areas and sensitivities and specificities at the
best threshold were higher for the tests based on chronic phase,
showing that the chronic phase is generally a better predictor of
survival. However, CD4 preservation was a better predictor of
survival than viral load in the acute phase.
Insights from modeling into the importance of CD4+ T
cells as a predictor
From the standard model of viral dynamics (Eq.3–5) we can get
some insights into the reasons why preservation of CD4+ T cells is
a better indicator of survival than viral load, although viral load
and CD4 levels are strongly (negatively) correlated. According to
the model, viral loads in the acute and chronic phases of infection
depend on baseline CD4 number and virus-dependent parame-
ters, such as virus infectivity, death rate of infected cells, virus
production by infected cells and free virus clearance, all of which
can be differently modified by individual host immune responses.
On the other hand, the fractions of remaining CD4+ T cells in the
acute (Eq.9) and chronic phases (Eq.10) only depend on the basic
reproductive ratio (Eq.6), i.e. a single number that is a
combination of all these individually varying parameters. This
means that, with a constant level of total immune response (model
parameters not depending on time) during the whole course of
disease, the CD4 preservation in the acute phase would completely
determine the final fraction of remaining cells in the steady-state.
However, the peak viral load (Eq.7) depends on different
individually varying parameters than the viral set point (Eq.8).
This means that two animals with the same peak viral load can
have different viral set points and different steady-state CD4+ T
cell levels, and therefore different long term outcomes, even for the
simple dynamics with constant total immune response described
by the model. For example, one animal can have a much higher
death rate of infected cells d than the other (having better CD8+ T
cell response), which may be compensated by a somewhat higher
infectivity b. Its basic reproductive ratio R0 (Eq.6) would then still
be lower than in the other animal, although both animals would
have the same peak viral loads (Eq.7). However, the animal with
the lower basic reproductive ratio would have higher acute and
chronic CD4 levels and lower set point viral load than the animal
with higher basic reproductive ratio. On the other hand, two
animals having the same CD4 nadir will always have the same
chronic CD4 level, irrespective of the specific parameters causing
CD4 depletion.
Is there irreversible damage to the immune system in the
acute phase?
We have shown that the prolonged low level of CD4+ T cells in
the chronic phase below the threshold of 24.1% of baseline leads
to early death, and that this low level can be predicted by the
CD4+ T cell level in the acute phase below 3.3% of baseline. What
Table 1. Summary of measures of accuracy of survival tests based on depletion of CD4+ T cells.
Test CD4+ T cells chronic phase (% of baseline) CD4+ T cells acute phase (% of baseline)
ROC area (standard error) 0.993 (60.008953) 0.938 (60.03299)
Best choice of threshold 75.9% 96.7%
Sensitivity 95.0% 84.2%
Specificity 93.3% 87.5%
doi:10.1371/journal.pone.0017180.t001
Table 2. Summary of measures of accuracy of survival tests based on viral load.
Test Set point viral load (RNA copies/mL) Peak viral load (RNA copies/mL)
ROC area (standard error) 0.977 (60.02428) 0.891 (60.05304)
Best choice of threshold 4.83610
4 4.79610
7
Sensitivity 94.7% 84.2%
Specificity 93.4% 87.5%
doi:10.1371/journal.pone.0017180.t002
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preservation in acute and chronic infection is just the result of the
intrinsic susceptibility of the animal (including the strength of the
immune response), which determines both acute and chronic
CD4+ T cell levels. Alternatively, if early CD4+ T cell depletion
compromised immune control and drove later disease progression,
then we expect that the level of CD4+ T cells in the chronic phase
should be worse than expected from a simple model based on
constant immune control. Thus, we need to first estimate the
expected relationship between the acute and chronic phases of
infection, and then observe if the latter is worse than expected.
We can make this estimate using the standard model of viral
dynamics (Eq.3–5). If we plot CD4+ T cell level in the chronic
phase T
*/T0 as a function of the fraction remaining in the acute
phase Tmin/T0, we obtain the universal curve shown as solid black
line in Figure 3A. Full circles represent the data for the controllers,
and open circles represent the progressors. The grey area encloses
CD4+ T cell levels in the acute phase lower than the survival
threshold, as determined by the ROC analysis. The pink area is
the fraction of remaining CD4 T cells in the chronic phase
corresponding to the acute levels in the grey interval, as predicted
by the model, if we assume constant immune response during the
whole course of disease. It is immediately obvious that, for very
low fractions of remaining CD4+ T cells in the acute phase, small
improvement in CD4 preservation results in much larger
improvement in the long-term outcome.
The horizontal dashed line in Figure 3A is the survival threshold
for the chronic preservation of 24.1% of CD4+ T cells from the
diagnostic test. If the immune response remained constant, 3.3%
remaining CD4+ T cells in the acute phase would result in 27%
remaining CD4+ T cells in the chronic phase, very close to the test
threshold of 24.1%. Using the chronic survival threshold predicted
by the model would result in only one more controller animal
being wrongly classified as progressor based on the remaining
CD4+ T cells in the chronic phase. The similarity between the
theoretical and experimental chronic preservation thresholds
corresponding to the preservation of 3.3% CD4+ T cells in the
acute phase suggests that the chronic preservation above the
survival threshold is a consequence of normal disease progression
from the acute to the chronic phase, with constant levels of
immune response differing among animals.
The standard model can also be used to estimate the amount of
CD4+ T cell recovery between the CD4 the acute and the chronic
phase, depending on the acute depletion, that we would expect to
see if the immune response were constant in time. The full black
line in Figure 3B shows this dependence. The amount of recovery
is presented as percent of baseline CD4+ T cell level (T
*-Tmin)/T0.
The amount of expected CD4 recovery increases rapidly with
increasing acute CD4+ T cell level, up to approximately 15%
preservation, and is very low when acute CD4+ T cells are almost
completely depleted. Therefore the lack of CD4+ T cell recovery
observed after extremely low acute levels does not need to be a
consequence of irreversible damage to the immune system, but
may be a normal progress in the case of a very susceptible animal.
When the data points appear below the theoretical curves in
Figures 3A or 3B, this means that the animals had fewer CD4+ T
cells in the chronic phase than expected from the acute phase. We
can see that most animals (with the exception of five controllers) do
worse than expected in the long run – most points are below the
theoretical curves in Figure 3A and 3B. In order to quantify how
much less the animals recover on average after the acute CD4 loss,
we calculate the ‘‘differential recovery’’ – the difference between the
actual recovery (T
*-Tmin)/T0 and the amount of recovery expected
ifthe immuneresponsewereconstant(asestimated fromthe model).
We obtain the overall median differential recovery of 216.9%,
meaning that over all, the animals do worse than expected by
16.9%. Progressors do worse than expected by (median) 18.8%,
while controllers do worse by (median) 3.9%, which is significantly
better than progressors (Figure 4, Mann-Whitney p,0.0001).
The progressors, who have lower levels of CD4+ T cells both in
acute and in chronic phase, recover less than expected in the
chronic phase. This suggests that weaker recovery might be
associated with the level of early CD4+ T cell depletion. In
Figure 5 we plot the differential recovery against the acute CD4
level (Figure 5A) and CD4 level in the chronic phase (Figure 5B).
In both cases there is a significant over-all positive correlation
(Spearman r=0.536, p=0.0009 in the acute phase and Spearman
r=0.745, p,0.0001 in the chronic phase). However, the
Figure 3. CD4+ T cells remaining in the chronic phase (as % of baseline) and their recovery as functions of the CD4+ T cells
remaining at nadir. Full line represents the relationship expected for constant level of immune control. Grey area is the level of CD4+ T cells at
nadir lower than the acute survival threshold of 3.3% of baseline. (A) Survival threshold of 24.1% of baseline based on chronic phase CD4 T cell level
(dashed line bordering the red area) almost exactly corresponds to the acute threshold, based on the assumption of constant immune response. The
animals with data points below the full line have less CD4+ T cells remaining in the chronic phase than expected from the nadir. (B) CD4+ recovery is
defined as the difference between the nadir and the chronic level. The points above the curve represent better than expected recovery. All animals
with the level of remaining CD4+ T cells lower than the survival threshold recover considerably less than expected.
doi:10.1371/journal.pone.0017180.g003
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in Figure 5A heavily relies on the cluster of points at very low CD4
fraction belonging to progressors. If we remove this cluster of
points with the acute CD4+ T cell level below 3.3% of baseline
(the acute survival threshold in the grey rectangle) the positive
correlation loses significance (Spearman r=0.346, p=0.1743).
This may indicate that either there is indeed some damage caused
by the loss of more than 96.7% CD4+ T cells in the acute phase,
but that preservation of more than 3.3% CD4+ T cells might be
sufficient for the maintenance of stable immune function.
On the other hand, if we remove the points below the chronic
survival threshold of 24.1% (the grey rectangle) from Figure 5B,
the significant positive correlation remains (Spearman r=0.681,
p=0.0052), which is expected because the chronic CD4+ T cell
level is the result of CD4 recovery after acute depletion.
Discussion
Better preservation of CD4+ T cells in the acute phase of SHIV
and SIV infection of rhesus macaques has been observed to lead to
better CD4 recovery and improved outcome of the disease later on
[2,3], even when the acute CD4 preservation was a consequence
of early interventions. Analysis of a data set of 35 SHIV-infected
rhesus macaques showed the expected result that long-term
survival is associated with set point viral loads below 4.83610
4 and
the chronic phase CD4+ T cell levels above 24.1% of baseline. In
this paper we addressed two questions: is there a similarly well
defined survival threshold for CD4+ T cell depletion and viral load
in the acute phase, and if there is, is it associated with a decline in
immune response later.
It was indeed possible to find a well defined survival threshold in
the acute phase: if CD4+ T cells in the acute phase drop below
3.3% of baseline, this loss is associated with almost no CD4
recovery in the chronic phase, and early death (in less than 600
days).
We used modeling to predict the hypothetical chronic phase
CD4+ T cell loss based on the CD4+ T cell level in the acute
phase assuming constant level of virus control between acute and
chronic phase. Constant virus control in this context would mean
the combined effect of intrinsic susceptibility of individual
animals at cellular level (e.g. ability to produce cytoplasmic
defence proteins) and all types of immune responses including
innate and adaptive immune mechanisms. While the relative
importance of these effects could shift during the disease course,
their combined effect on the control of viral replication may still
be constant.
Modeling revealed two main features of the disease progress
between the acute and the chronic phase, expected with
unchanged immune control. Firstly, if the cells targeted by virus
become highly depleted (more than 95%) in the acute phase, a
small improvement in virus control would lead to a small increase
in their numbers in the acute phase, and a comparatively much
larger increase in the chronic phase. Similar pattern was observed
in SIV-infected rhesus macaques, where the variation in the
intrinsic ability of their CD4+ T cells to produce TRIM5a had
greater effect in late than in early infection [18].
Secondly, if we define CD4 recovery as the difference between
the CD4 count in the acute and chronic phase, then we find that
Figure 5. Differential recovery is significantly positively correlated to CD4+ T cell preservation: (A) in the acute phase (Spearman
r=0.536, p=0.0009); (B) in the chronic phase (Spearman r=0.745, p,0.0001). Grey rectangles represent CD4+ T cell levels below the survival
thresholds. If we consider only the points with CD4+ T cells above the survival thresholds (outside the grey rectangles), (A) in the acute phase the
correlation is no more significant (Spearman r=0.346, p=0.1743), but (B) it is still significant in the chronic phase (Spearman r=0.681, p=0.0052)
doi:10.1371/journal.pone.0017180.g005
Figure 4. Differential recovery in progressors and controllers.
We defined the ‘‘differential recovery’’ as the difference between the
actual recovery and the amount of recovery expected if the immune
response were constant. The differential recovery in progressors was
significantly lower than in controllers (Mann-Whitney p,0.0001).
doi:10.1371/journal.pone.0017180.g004
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remaining CD4+ T cells at nadir even without any deterioration in
immune control. In other words, lower CD4 recovery in the
chronic phase of viremia in animals with severe acute CD4
depletion could be just a consequence of a constant high level of
susceptibility in these animals.
We compared the observed CD4 recovery in the chronic
phase to the expected recovery estimated from the level of CD4
preservation at nadir assuming constant level of virus control.
We found that recovery was significantly less than expected in
the animals with nadir CD4 preservation below the survival
threshold. In addition, we observed that the difference between
observed and expected recovery was over-all significantly
positively correlated with CD4 preservation in the acute phase,
but that the correlation lost significance when we removed the
animals with the acute CD4+ T cell level lower than the survival
threshold. These observations are consistent with a model in
which there is a threshold level of acute CD4+ Tc e l l s( 3 . 3 %o f
baseline), below which there is a decline in immune function
and a tendency for rapid progression. Possible reasons could be
insufficient CD4 help necessary for sustained immune control,
or early lymphoid or mucosal tissue damage [19] due to
inflammatory processes associated with low CD4+ T cell levels.
In contrast, when CD4+ T cells in acute phase were preserved
above the threshold, the total effect of immune control did not
seem to decline, despite the virus-specific CD8+ T cells peaking
in acute phase and subsiding later. In addition, the majority of
controller animals with less than threshold acute depletion were
vaccinated, suggesting thati nS H I Vi n f e c t i o nt h ee a r l y
preservation of T cells caused by vaccination can make lasting
immune control possible.
In CCR5-tropic SIV and HIV infections, total body CD4+ T
cell loss in the primary phase is almost never as extreme as 97%, so
that it should not compromise later antiviral responses. This
suggests that the acute loss of CD4+ T cells is unlikely to
contribute to the late decline in virus control in HIV, which may
be caused by other complications occurring later in the disease
course. However, many studies have shown that the loss and
qualitative impairment of HIV-specific T-cell help occurs very
early in infection and cannot therefore be predicted by the overall
numbers of circulating CD4+ T-cells.
Materials and Methods
Experimental data
In a previously published study [13], 35 rhesus macaques
(Macaca mulatta) were challenged intravenously with 50% monkey
infectious doses of CXCR4-tropic SHIV89.6P. 14 animals in this
group were unvaccinated controls, while 21 were vaccinated with
a variety of regimens, consisting of SIV gag-containing plasmid
DNA (with different adjuvants), modified vaccinia Ankara, and
adenovirus type 5 vectors, as previously reported [13]. The
vaccinated animals were challenged at 6 weeks or at 12 weeks after
the final boost. Viral loads and CD4+ T-cell counts were
monitored in peripheral blood every 2 to 4 days until 4 weeks
after infection and then weekly.
Data analysis
Initially, we divided the animals into progressors, which died
before day 600 of infection, and controllers, which survived
beyond 600 days. We designed diagnostic tests based on CD4+ T
cell level and on viral load in order to predict early death, i.e. we
found the threshold CD4+ T cell level and threshold viral load in
acute and chronic phase of infection that best corresponded to the
classification into progressors and controllers. As the acute phase
measures we chose the CD4+ T cell level at nadir and the peak
viral load. In the chronic phase we used the set point CD4+ T cell
level and viral load, which we defined as the averages between day
100 and day 200 of infection, or between day 100 and death if the
animal died before day 200. All animals survived longer than 100
days.
For every recorded value of a particular measure (CD4+ T cell
level or viral load) chosen as a threshold, we found the number of
animals correctly or wrongly classified as progressors (true positives
TP or false positives FP respectively), and correctly or wrongly
classified as controllers (true negatives TN or false negatives FN).
The accuracy of a particular classification is measured in terms of
specificity and sensitivity [20]. The sensitivity of the test for a given
choice of threshold is the fraction of all progressors (TP+FN) that
are correctly classified as progressors (TP); and the specificity is the
fraction of all controllers (TN+FP) that are correctly classified as
controllers (TN),
sensitivity~TP=(TPzFN) ð1Þ
specificity~TN=(TNzFP) ð2Þ
For an ideal indicator of survival, there would exist a threshold
(or a threshold interval) for which all progressors and controllers
classified correctly (FP=FN=0), i.e. sensitivity and specificity
would both be equal to unity for the best choice of threshold,
while one of them would be less than unity for values of threshold
outside the correct range. This is not the case for any of the
measures that we have chosen. We defined the best choice of
threshold as the one that maximizes both specificity and
sensitivity, i.e. for which sensitivity and specificity had the closest
values.
Sensitivity and specificity can be used to assess a classification
based on the chosen threshold value of the test quantity (in our
case CD4 depletion or viral load). Sensitivity and specificity for the
best choice of threshold indicate how accurate is a test based on a
particular quantity (how well defined is the threshold value). A
more rigorous way to evaluate the overall accuracy of a test based
upon a particular measure is to plot sensitivity as a function of (1-
specificity) for all recorded values of the test quantity and find the
area under the curve (the so-called receiver-operator characteristic
(ROC) area [21]). If controllers tend to test higher, ROC area
represents the probability that the test value for a randomly chosen
controller is higher than the test value of a randomly chosen
progressor (and opposite for tests for which controllers test lower).
If a perfectly clear-cut threshold value separated controllers and
progressors, the ROC area would be equal to unity. Larger ROC
area indicates that a test based on a particular quantity is more
accurate. We compared the ROC areas, obtained using different
quantities as the basis of classification on the same data set, using
the method described in [22].
Data analysis was performed using Graphpad Prism v.5.0a for
Mac OSX.
Model
The standard model [23,24,25,26] of viral dynamics has been
used to study HIV infection for a number of years [27]. We have
shown that it describes well the dynamics of viral load and CD4+
T cells in the acute phase of SHIV89.6P infection [28,29], where we
have access to both viral load and target cell number.
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dT
dt
~l{dTT{bVT ð3Þ
dI
dt
~bVT{dI ð4Þ
dV
dt
~pI{cV ð5Þ
describes the relationships between the change in the number of
uninfected cells T that are targets for the virus, infected cells I and
free virus particles V in a given volume of blood or tissue. The
parameters l, the production rate of new targets, and dT, the loss
rate of target cells, describe the disease-free target cell dynamics.
The disease-free equilibrium number of target cells is equal to
T0=l/dT. The infectivity b characterizes the probability of a virus
particle infecting a target cell, and d is the death rate of infected
cells, d&dT. Free virus is produced by infected cells at the rate p
and is cleared at the rate c. In this model, different types of
immune response are assumed to modify the virus parameters d, c,
b and p. All the parameters (and consequently the immune
response) are assumed to be constant in time.
In this simple model, the course of the infection is largely
determined by the basic reproductive ratio of the virus R0.I ti s
defined as the number of infected cells generated initially by one
infected cell in its lifetime, and as such is a measure of viral
replication. In terms of the parameters for this model it is
R0~T0
bp
dc
: ð6Þ
The infection can spread only if R0.1. In this case, viral load
generally grows exponentially to the peak VP, which for the
parameter range characteristic for SHIV infection can be
approximated by [24,28]
VP~
d
b
R0{1{lnR0 ðÞ : ð7Þ
After reaching the peak, viral load decays and finally reaches the
set point value V
*,
V ~
dT
b
(R0{1): ð8Þ
Peak viral load and viral set point are positively correlated to the
basic reproductive ratio, but in addition depend separately on
different viral parameters.
Target cells drop to the nadir Tmin, then partly recover, and
settle at the steady-state value T
*. The nadir of target cells in the
standard model applied to SHIV is the solution of the equation
[28]
Tmin
T0
{
1
R0
ln
Tmin
T0
, ð9Þ
and the set point number is
T ~T0=R0: ð10Þ
The fractions of target cells remaining at nadir Tmin/T0 and at
the steady state T
*/T0 only depend on the basic reproductive ratio
R0. This means that the dependence of the preserved steady state
target cell fraction on the remaining fraction at nadir can be
represented as a single universal curve parametrized by R0. Note
that there is no fitting required for this curve – for every value of
R0.1 there is only one value for the preservation of target cells
Tmin/T0 at nadir and only one corresponding value for the
preservation T
*/T0 at the steady state. The relationship between
the remaining nadir and chronic fractions is universal for all viral
infections for which the basic model applies, provided that the
uninfected target cell replacement and loss rates are small, and
that the virus clearance rate is much higher than the death rate of
infected cells (the conditions under which the expressions Eq.7-9
were derived [28]). The important limitation is that this
relationship can only be useful when the target cell abundance
can be measured directly. For this reason the model is most easily
applied to the infection with CXCR4-tropic virus.
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